(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 November 2006 (02.11.2006)

PCT

(10) International Publication Number
WO 2006/114704 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/IB2006/001053

(22) International Filing Date: 13 April 2006 (13.04.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/675,311 26 April 2005 (26.04.2005) US

(71) Applicant *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BAUER, Christopher Todd** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **BOURNER, Maureen, Jeri** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **BOYLE, Melanie** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **CASPERSON, Gerald Fries** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **GRIGGS, David William** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **HEAD, Richard David** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **JOY, William Dean** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **MAZZARELLA, Richard Allen** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **MINTER, Ralph Raymond** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **MOFFAT, Mark Allen** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **THIELE, Barrett Richard** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **VANARSDALE, Todd Lee** [US/US]; Pfizer Global Research and Development, Agouron/Pfizer, La Jolla, 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agents: **FULLER, Grover, F., Jr.** et al.; c/o Drouin Stéphane, Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
22 March 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: P-CADHERIN ANTIBODIES

(57) Abstract: The present invention relates to antibodies including human antibodies and antigen- binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P- cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

WO 2006/114704 A3